All In Biotech

Drug Trial Radar · NCT04150497

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

45

Actual

Start

Oct 14, 2019

Primary completion

Sep 16, 2026

Study completion Dec 2027

Sponsor

Lead sponsor
Cellectis S.A.Industry
Sponsor type
Industry
First posted
Nov 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to determine the optimal dose of CLLS52 as part of the FCA LD regimen followed by the Recommended Phase 2 Dose (RP2D) of UCART22 and evaluate the safety and efficacy of UCART22.

Conditions

  • B-cell Acute Lymphoblastic Leukemia

Interventions

  • UCART22Biological

    Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen

  • CLLS52Biological

    A monoclonal antibody that recognizes a CD52 antigen

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs), serious adverse events (SAEs), and dose limiting toxicities (DLTs) throughout the study in relation to UCART22 and/or lymphodepletionTime frame: 24 months
  2. Percentage of participants achieving a complete response (CR) or CR with incomplete hematologic recovery (CRi) according to the Response Criteria for acute lymphoblastic leukemia (ALL) assessed by independent response review committeeTime frame: Within 3 months at Day 28, Day 56, Day 84

Locations

20 sites in 2 countries. Site status is shown where the registry gives one.

  • Children's of Alabama

    Birmingham, Alabama

  • University of California Los Angeles (UCLA)

    Los Angeles, California

  • UCSF Benioff Children's Hospital

    San Francisco, California

  • UCHealth Cancer Care - Anschutz Medical Campus - University of Colorado Cancer Center

    Aurora, Colorado

  • SCRI - Colorado Blood Cancer Institute

    Denver, Colorado

  • University of Illinois Medical Center

    Chicago, Illinois

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care

    New York, New York

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • SCRI - TriStar Centennial Medical Center

    Nashville, Tennessee

  • SCRI - St. David's South Austin Medical Center

    Austin, Texas

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Methodist Hospital - San Antonio

    San Antonio, Texas

  • University of Wisconsin - Madison

    Madison, Wisconsin

  • Centre Hospitalier Universitaire Nantes - Hôtel Dieu

    Nantes, France

  • Hôpital Saint-Louis

    Paris, France

  • Hôpital Robert-Debré AP-HP

    Paris, France

  • Centre Hospitalier Lyon-Sud

    Pierre-Bénite, France

  • Hôpital Pontchaillou

    Rennes, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.